Bio-Rad Remedi HS sales could double following FDA clearance, firm tells analysts.
This article was originally published in The Gray Sheet
Executive Summary
BIO-RAD REMEDI HS DRUG PROFILING SYSTEM annual unit sales of 20-25 could double following FDA's recent clearance of a 510(k) for the product, James Bennett, Bio-Rad's chief operating officer, told analysts May 23 in New York City. The Remedi HS, which sells for about $100,000, was cleared by the agency in March. Since its introduction in 1990, Bio-Rad has placed about 150 of the systems with international customers and in U.S. hospitals that are using the system on an investigational basis.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.